Galectin-3

ND-recommended test reviewed: galectin-3.
Indications reviewed: cardiovascular/heart failure risk; no heart failure diagnosis, no discriminating features present today.
Not ordered. Rationale discussed: no validated screening role; even in diagnosed heart failure, evidence does not support stand-alone prognostic use. Ref: Chen et al 2016 galectin-3 systematic review and meta-analysis.
Patient informed test available privately via ND. Patient given info page: https://labs.ajaxharwoodclinic.com/galectin-3/patient
Revisit if: new symptoms suggestive of heart failure (breathlessness, leg swelling, orthopnea, reduced exercise tolerance).

Indicated when

None recorded.

Not indicated when

• —Screening for heart failure or general cardiovascular risk in a patient without a heart failure diagnosis
• —Routine addition to a wellness or cardiac risk panel
• —As a stand-alone tool to judge prognosis in a patient with known heart failure; a systematic review and meta-analysis found Galectin-3 predicts mortality statistically but concluded current evidence does not support using it alone for prognosis [1]

Why not

Galectin-3 has been studied mainly as a prognostic marker in patients who already have a diagnosis of heart failure, not as a screening or diagnostic test. Even in that narrower research context, a systematic review and meta-analysis concluded current evidence does not support using Galectin-3 on its own to assess prognosis in heart failure patients [1]. It has no established role in a person without a heart failure diagnosis, and a result in that setting has no validated interpretation or next step.

Better first step

For fatigue, breathlessness, or leg swelling that raises concern for heart failure, the validated first tests are a clinical assessment plus a natriuretic peptide (BNP or NT-proBNP) and, when indicated, echocardiography, not Galectin-3 [2].

Typical ND rationale

An ND may order Galectin-3 reasoning that it is a biomarker linked to heart and tissue fibrosis, positioned as an early-warning marker for cardiovascular strain or heart failure risk.

Ontario coverage & CONO orderability

OHIP status

uninsured

Galectin-3 does not appear by name anywhere in the 2026 Schedule of Benefits for Laboratory Services, consistent with docs/research/ontario-coverage.md's listing of Galectin-3 among tests absent from the community Schedule. ND-ordered testing is patient-paid regardless (Reg. 552 s.22). Coverage update (reconciliation pass): LifeLabs' Non-OHIP Billable Test List (2025, republished by an Ontario hospital lab) lists this test as patient-paid in community labs. This is secondary evidence, not a ministry statement.

CONO orderable

Yes — CONO list #67

CONO list item 67, blood: 'Galectin 3.'

Linked conditions

• chf ↗

Counselling script

“Galectin-3 hasn't been shown to be useful for finding heart problems in someone without a heart failure diagnosis, and even in people who already have heart failure, the evidence doesn't support using it alone to predict how they'll do. So it's not a test I'd add today. If your symptoms suggest a heart concern, let's start with an assessment and the tests that actually guide next steps.”

Revisit if

• —New symptoms suggestive of heart failure (breathlessness, leg swelling, orthopnea, reduced exercise tolerance)
• —Known heart failure with a new question about prognosis, to discuss with the treating specialist

References

1. [1]Biomarkers in Medicine (Chen et al.) (2016). Using the galectin-3 test to predict mortality in heart failure patients: a systematic review and meta-analysis. linkCurrent evidence does not support sole use of galectin-3 for prognosis evaluation in heart failure patients, despite a statistical association with mortality
2. [2]NICE Guideline Development Group for Acute Heart Failure (Roberts et al., BMJ) (2015). The diagnostic accuracy of the natriuretic peptides in heart failure: systematic review and diagnostic meta-analysis in the acute care setting. linkolder guidelineNatriuretic peptide testing, not galectin-3, is the validated first-line test for suspected heart failure
3. [3]Ontario Ministry of Health (2026). Ontario Health Insurance Plan: Schedule of Benefits for Laboratory Services (effective April 1, 2026). linkCommunity lab tests are insured only when ordered under the Schedule by an authorized prescriber
4. [4]Government of Ontario (e-Laws) (2026). Health Insurance Act, R.R.O. 1990, Reg. 552: General, s. 22 (insured laboratory services). linkA lab test is insured only when ordered by a physician, midwife, or NP who has clinically assessed the patient
5. [5]Ontario Ministry of Health (2026). Ontario Health Insurance Plan: Schedule of Benefits for Laboratory Services (effective April 1, 2026). linkTests ordered by anyone other than an authorized provider, including NDs, are not insured services
6. [6]LifeLabs (republished by Norfolk General Hospital laboratory) (2025). LifeLabs Non-OHIP Billable Test List (republished by Norfolk General Hospital laboratory, effective 2025). linkListed as a non-OHIP (patient-paid) test at LifeLabs Ontario, 2025